The meeting, which comes a year after the agency issued a complete response letter in October 2025,2 was held from 8:30 am-3 pm ET and was open to public.
|Articles|May 2, 2022
BHVI announces Myopia Awareness Week 2022
Author(s)Alex Delaney-Gesing, Senior Editor
Set for May 23-28, the global initiative aims to bring attention to the global epidemic of myopia cases in children.
Advertisement
Included in this year’s week-long event are a range of educational resources for eye care practitioners (ECPs), parents, and advocates of
Social media content and prominent individuals within the global eye care field will also provide tips and recommendations for parents and children to reduce the risk of onset or progression of myopia.
Additional resources and information on the campaign can be found
Advertisement
Related to this article
FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia.
From treating myopic complications to preventing them, eye care providers have ample opportunity to close a collaborative care gap.
Presenters from AAOpt26's research symposium share their findings, applications for optometric practice, and goals for future study.
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session.
Magdalena Stec, OD, FAAO; Noreen Shaikh, OD, FAAO; Huizi Kelly Yin, OD, FAAO; and Brenda Bohnsack, MD, PhD, detail their AAOpt 2026 session in Anaheim, California.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
The untapped partnership between retinal specialists and optometrists in myopia care
2
From our Editorial Board: Comments from the FDA Advisory Committee meeting on SYD-101
3
More magic in Anaheim: Highlights from AAOpt 2026
4
FDA approves ranibizumab biosimilar Lucamzi for wet AMD
5